Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p= 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p= 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.
背景/目的：在REGOMA试验中，瑞戈非尼相比洛莫司汀显示出总生存期优势，并已成为指南中推荐的复发性胶质母细胞瘤治疗方案。本研究旨在评估瑞戈非尼作为三线治疗，对基于贝伐珠单抗治疗期间进展的复发性胶质母细胞瘤患者的有效性和安全性。方法：这项在土耳其进行的回顾性多中心研究纳入了2021年至2023年间在19个肿瘤中心接受治疗的65例患者。主要纳入标准包括经组织学证实的异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤、基于贝伐珠单抗的二线治疗后进展，以及美国东部肿瘤协作组（ECOG）体能状态评分≤2分。患者在每个4周周期的前3周每日一次口服瑞戈非尼160 mg。结果：患者中位年龄为53岁（范围18-67岁），中位无进展生存期为2.5个月（95%置信区间：2.23-2.75），中位总生存期为4.1个月（95%置信区间：3.52-4.68）。与未接受后续治疗的患者相比，瑞戈非尼治疗后接受后续治疗的患者中位总生存期有所改善（p=0.022）。ECOG评分为0-1分的患者无进展生存期长于ECOG评分为2分的患者（p=0.042）。安全性特征与REGOMA试验一致，未观察到药物相关死亡。结论：瑞戈非尼作为基于贝伐珠单抗治疗后复发性胶质母细胞瘤的三线治疗，显示出良好的疗效和安全性。本研究支持瑞戈非尼的应用，并强调需要进一步的随机研究以验证其作用并优化治疗策略。
肿瘤(癌症)患者之家